

Appointment of Non-Executive Director– Dr Jeffrey Le Bengier

Artrya's Board strengthened with experienced U.S. healthcare executive

PERTH, Australia, 19 February 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce the appointment of Dr Jeffrey Le Bengier to the Board as a Non-Executive Director.

Bernie Ridgeway, Chair of Artrya commented:

"I'm very pleased to welcome Dr Le Bengier to the Artrya Board. His decades of experience leading U.S. multi-discipline healthcare organisations through significant growth and operational transformation brings a powerful combination of insight and discipline to our Board. Jeffrey has spent his career successfully navigating the complex U.S. healthcare environment and driving innovation in patient-centred delivery. His experience will be invaluable as we accelerate our U.S. commercial roll-out and engage with large U.S. healthcare groups as partners and customers."

Expanding board capability ahead of U.S. commercialisation push

Dr Jeffrey Le Bengier is a senior healthcare executive and physician with more than two decades of leadership experience across medical groups and value-based care delivery. He served as CEO of Summit Medical Group from 1999 and as CEO of Summit Health from 2019, following the merger with CityMD, which created a multi-state organisation with more than 2,000 providers across 680 locations, offering primary, speciality and urgent care. He became Executive Chairman of Summit Health in 2021, supporting execution of their long-term strategic plan.

During his tenure, Dr Le Bengier oversaw the rapid growth and transformation of Summit Health into a leading multi-discipline healthcare provider. Summit Health was acquired for US\$8.9B in November 2022 by VillageMD, part of the Walgreens Boots Alliance (NASDAQ:WBA), creating one of the largest independent healthcare groups. The Walgreens Boots Alliance was acquired for US\$10.0B in August 2025, by private equity firm Sycamore Partners.

Dr Le Bengier will be the second U.S. based Director to join Artrya's board, bringing his extensive commercial experience building a successful, high growth U.S. healthcare business, which is the key focus for Artrya.

Dr Le Bengier is board certified in facial plastic and reconstructive surgery, otolaryngology, and head and neck surgery. He is a fellow of the American College of Surgery, American Rhinologic Society, and the American Society of Head and Neck Surgery. He earned his medical degree from New York Medical College and completed two residencies at Mount Sinai Medical Center. Throughout his career, Dr Le Bengier has been an advocate for simplified and integrated care models, digital transformation, and the expansion of outpatient services.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: investors@artrya.com